Olaparib Maintenance Therapy Improves Survival in Relapsed, BRCA-Positive Ovarian Cancer

Treatment with olaparib in the maintenance setting extended overall survival by more than a year in women with platinum-sensitive relapsed ovarian cancer with BRCA1/2 mutations.

Source: CancerNetwork - May 13, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news